Amyotrophic Lateral Sclerosis Registry in Thailand
Thai ALS Regis
A Prospective, Multicenter Registry Study of Amyotrophic Lateral Sclerosis in Thailand
2 other identifiers
observational
100
1 country
1
Brief Summary
This is a prospective, observational, multicenter registry designed to collect comprehensive clinical, genetic, and outcome data from patients diagnosed with amyotrophic lateral sclerosis (ALS) across Thailand. The registry will establish a national dataset to describe epidemiology, clinical presentation, progression, and treatment outcomes, and will serve as a platform for future clinical and translational research.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Mar 2025
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 1, 2025
CompletedFirst Submitted
Initial submission to the registry
August 27, 2025
CompletedFirst Posted
Study publicly available on registry
September 16, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2030
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 31, 2030
September 16, 2025
September 1, 2025
5.8 years
August 27, 2025
September 14, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Survival
Time Frame: From enrollment until death from any cause (assessed continuously, with updates at each follow-up). Outcome: Overall survival in ALS patients across Thailand, with survival curves stratified by demographic, clinical, and genetic factors.
10 years
Secondary Outcomes (7)
ALS Functional Decline
10 years
Disease Staging Progression
10 years
Respiratory Outcomes
10 years
Changes in health-related quality of life over time.
10 years
Cognitive and Behavioral Profile
10 years
- +2 more secondary outcomes
Eligibility Criteria
ALS patients attending university hospitals, tertiary neuromuscular clinics, and referral hospitals in Thailand.
You may qualify if:
- Diagnosis of ALS according to El Escorial or Gold Coast criteria
- Age ≥ 18 years
- Ability and willingness to provide informed consent
You may not qualify if:
- Patients unwilling to provide informed consent
- Patients with alternative diagnoses mimicking ALS
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
King Chulalongkorn Memorial hospital, The Thai Red Cross Society
Pathum Wan, Bangkok, 10330, Thailand
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 10 Years
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Priciple Investigator
Study Record Dates
First Submitted
August 27, 2025
First Posted
September 16, 2025
Study Start
March 1, 2025
Primary Completion (Estimated)
December 31, 2030
Study Completion (Estimated)
December 31, 2030
Last Updated
September 16, 2025
Record last verified: 2025-09
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, CSR
- Time Frame
- IPD will be available beginning 6-12 months after publication of the primary results and for up to 5 years thereafter.
- Access Criteria
- Requests for access should be directed to the Principal Investigator via institutional contact email. Applicants will be required to submit a research proposal outlining objectives, methods, and intended use of the data. Approval will be contingent on adherence to ethical and scientific standards, and execution of a data sharing agreement.
De-identified individual participant data (IPD) underlying the results of this study (including clinical, demographic, and outcome measures) will be made available to qualified researchers upon reasonable request, following publication of the primary results. Access will be provided to investigators whose proposed use of the data has been approved by an independent review committee to ensure scientific merit and compliance with ethical standards. Data will be shared through secure data transfer under a data sharing agreement that protects participant confidentiality. Supporting documents, including the study protocol, statistical analysis plan, and informed consent form, will also be made available where applicable.